Poisoning and Drug Reference: Recent Episodes
ReachMD
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Host: Matt Birnholz, MD
Among the most touted candidates in the hunt for effective coronavirus treatments are the antimalarial drugs chloroquine and its derivative, hydroxychloroquine. Will these drugs become effective treatment and post-exposure prophylaxis agents?
Published March 23, 2020
Host: Andrew Wilner, MD, FACP, FAAN
As physicians, we know that vaccines help protect people from preventable diseases, but somehow this message is getting lost among our patients. With more parents than ever choosing to skip the needle, Dr. Andrew Wilner dives into the 16th chapter of his book, Bullets and Brains, where he discusses the widespread benefits of vaccines and how they not only protect your patients’ children, but all of us.
Host: Andrew Wilner, MD, FACP, FAAN
Up until 2011, there was no FDA-approved antivenom for scorpion stings—until a very concerned pediatrician created one that came with seemingly miraculous results. Dr. Andrew Wilner breaks down this overlooked health threat and the development of its antivenom, which he explores in his book of essays called Bullets and Brains.
The FDA has made strides in improving transparency and data access, and has implemented tools to allow the pharmaceutical industry and the public to transform raw data into usable information. One of these tools is called the FDA Adverse Event Reporting System (FAERS) Public Dashboard. In this episode, the architects of the FAERS Public Dashboard – Deputy Director of the Regulatory Science Staff Suranjan De, and Acting Team Lead in Regulatory Science Information Sanjay Sahoo—both of CDER’s Office of Surveillance and Epidemiology, highlight their work with this new online tool.
To explore the origin of our country’s opioid epidemic, Mark Masselli and Margaret Flinter speak with Pulitzer Prize-winning Barry Meier, author of Pain Killer: An Empire of Deceit and the Origin of America's Opioid Epidemic which dives into the pivotal role Purdue Pharma, makers of the narcotic OxyContin, played in the greatest public health crisis of the 21st century.
The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly.
A link to the full communication detailing specific information for health care professionals and a list of FDA-approved GBCAs can be found at www.fda.gov/Drugs/DrugSafety
Released 4/25/2018
Host: Maurice Pickard, MD
Guest: Carl Hart, MD
Carl Hart, who grew up in one of Miami’s toughest neighborhoods, escaped a life of crime and drugs and avoided becoming one of the crack addicts he now helps treat as the Chair of the Department of Psychology at Columbia University. His landmark, controversial research is redefining our understanding of addiction and demonstrates how personal experience and scientific study can inform and validate each other for a deeper understanding of human behavior and addiction.
Host Dr. Maurice Pickard talks with Dr. Hart, author of the book High Price, about the relationship between drugs and pleasure, choice, and motivation, both in the brain and in society. They explore how his research sheds new light on common ideas about race, poverty, and drugs, and explain why current policies are failing.
Host: Brian P. McDonough, MD, FAAFP
According to a report from the Trust for America’s Health, an estimated 1.6 million people could die from drugs, alcohol, and suicide in the next ten years. This is a 60% increase from the past decade.
Host Dr. Brian McDonough talks with John Templeton Jr, President of Footprints Beachside Recovery Center in Florida, about treating addiction and what doctors need to know about reducing opioid addiction risk in their pain medication management.
Host: Brian P. McDonough, MD, FAAFP
Over 33,000 lives were lost to opioid overdose in 2015, translating into 91 people dying each day, according to the most recent CDC data. Reducing exposure to prescription opioids, for situations where the risks of opioids outweigh their benefits, is a crucial part of reversing this trend.
Host Dr. Brian McDonough explores alternative options to prescription opioids with addiction specialist Dr. Isaac Alexis, Medical Director of the Lifeline Addiction Center in Beckley, WV.
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.
Released on December 21, 2017
The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.
Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch.
A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety.
Released 12/19/2017
The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.
A link to the full communication detailing information for health care professionals and the Data Summary can be found at www.fda.gov/DrugSafetyCommunications.
Released 12/20/2017
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. BACKGROUND: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution.
METHODS: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation.
RESULTS: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). …
Many listeners may be familiar with the FDA's Adverse Event Reporting System or FAERS. Data in FAERS supports the FDA's post-marketing safety surveillance program for drug products and therapeutic biologic products. Recently, CDER's Office of Surveillance and Epidemiology created and released a tool that makes FAERS data easier to query and retrieve. This new interactive dashboard is designed to expand access of FAERS data to the general public.
Dr. Janet Woodcock, Director of the FDA Center for Drug Evaluation and Research, discusses the advantages of the tool as well as its limitations.
Host: Brian P. McDonough, MD, FAAFP
Every year, 1 in 6 Americans get sick from eating contaminated food.
USDA Food Safety expert Sarah Lichtman joins host Dr. Brian McDonough to discuss ways to safely handle food, prevent food poisoning, and minimize risk of foodborne illnesses.
FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complications of sickle cell disease.
Released August 17, 2017
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
Released July 25, 2017
The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Released May 30, 2017.
FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
Released May 22, 2017
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Released May 18, 2017
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Released May 17, 2017
Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk.
Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.
Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch.
A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov.
Released 5/16/2017
In the FDA's inaugural Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks with hosts Dr. Sanjeeve Bala and Dr. Abhilasha Nair about this new podcast series.
The Food and Drug Administration (FDA) is restricting the use of codeine and tramadol medicines in children. Codeine is approved to treat pain and cough, and tramadol is approved to treat pain. These medicines carry serious risks, including slowed or difficult breathing and death, which appear to be a greater risk in children younger than 12 years, and should not be used in these children. These medicines should also be limited in some older children. Single-ingredient codeine and all tramadol-containing products are FDA-approved only for use in adults. The FDA is also recommending against the use of codeine and tramadol medicines in breastfeeding mothers due to possible harm to their infants.
As a result, the FDA is requiring several changes to the labels of all prescription medicines containing these drugs. These new actions further limit the use of these medicines beyond the 2013 restriction of codeine use in children younger than 18 years to treat pain after surgery to remove the tonsils and/or adenoids. The FDA is now adding:
- FDA’s strongest warning, called a Contraindication, to the drug labels of codeine and tramadol alerting that codeine should not be used to treat pain or cough and tramadol …
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough chats with Deadly Prescription author Dr. Robert Marx, Professor of Surgery and Chief of the Division of Oral and Maxillofacial Surgery at the University of Miami School of Medicine. The two discuss powerful impacts that corporate conflicts of interest from pharmaceutical companies can have on patient health.
Host: Lea Ann Chen, MD
Guest: Gary Lichtenstein, MD
Recorded on location at the Crohn’s & Colitis Foundation’s Annual Meeting in Orlando, host Dr. Lea Ann Chen, Assistant Professor of Medicine at New York University, discusses potential complications of biologics with Dr. Gary Lichtenstein, Professor of Medicine at the Hospital of the University of Pennsylvania.
In this session of Beyond the Data carrying forward ideas discussed at CDC's Public Health Grand Rounds, Dr. Phoebe Thorpe and Dr. Larry Garber expand on the reasons for medication non-adherence by patients, and priority considerations for helping reduce this risk.
Host: Patrice L Basanta-Henry, MD, MHSc, FACOG
Prescription drugs are often essential to the management of both acute and chronic pain. However, misuse, abuse and additions to these products, especially opioids, have become a worldwide epidemic. Since 1999, the number of overdose deaths involving opioids have almost quadrupled in the United States.
Host Dr. Patrice Basanta-Henry talks with psychiatrist and addiction medicine specialist Dr. Nzinga Harrison, CMO of Anka Behavioral Health Inc., about the physician's role in the face of this opioid epidemic.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU School of Medicine.
Dr. Gianos discusses the effectiveness, potential side effects, and patient outcomes with PCSK9 antibodies for management of dyslipidemia.
[Read the Article]
The increasing cost of prescription drugs in the United States has become a source of growing concern for patients, prescribers, payers, and policy makers. A new study examined the reasons for these high prices and also suggests policy changes that could help contain costs.
Researchers from Brigham and Women’s Hospital reviewed the medical and health policy literature on prescription drug prices in the U.S. and found high drug costs stem from various factors such as market exclusivity, limitations on payers and their ability to negotiate prices, and limitations on competition.
The researchers state that the most realistic short-term strategies include enforcing stricter requirements for exclusivity rights, ensuring timely generic drug availability, providing greater opportunities for price negotiation by patients, and effectively educating patients, prescribers, payers, and policy makers about these choices.
[Watch more videos of The JAMA Report]
Host: Brian P. McDonough, MD, FAAFP
An old adage states "There's many a slip between the cup and the lip." Applied to drug delivery, dosing, and compliance by patients, this phrase couldn't be more accurate. Drug information and clinical decision support systems are evolving to address problems in getting the right medications to the right patients, but more work needs to be done.
Joining Dr. Brian McDonough to discuss barriers and solutions to medication-related decision support is Dr. Shobha Phansalkar, Director of Informatics and Clinical Quality Control at the Clinical Drug Information Division of Wolters Kluwer. Additionally, she is an Assistant Professor in Medicine at the Division of General Medicine and Primary Care, Brigham and Women’s Hospital and Harvard Medical School.
Host: Jennifer Caudle, DO
Addictions to opioids have soared since the 1990's. It's now estimated that as many as 36 million people worldwide abuse opiods. The medical community not only assumes the heavy responsibility of confronting this epidemic in clinical practice, but also shoulders a significant amount of blame from the general public for overprescribing opioid medications. Where should clinicians on the front lines of care start to address both the clinical priorities and the encumbent social responsibilities of opioid abuse?
Dr. Anita Gupta, Associate Professor and Vice Chair of the Division of Pain Medicine in the Department of Anesthesiology at Drexel University School of Medicine, joins Dr. Jennifer Caudle to discuss the call to action for safer pain management in this era of prescription drug abuse.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes Dr. Charles Pollack, Professor of Emergency Medicine and Director of the Jefferson Institute of Emerging Health Professions at Thomas Jefferson University School of Medicine. Dr. Pollack's team recently formed the Center for Medical Cannabis Education & Research, tasked with providing expert-developed, unbiased information to clinicians and patients about the medical uses of marijuana and cannabinoid-focused therapies.
The two discuss current clinical recommendations for cannabis based on the available research, and where the benefits and risks collide amidst mass public interest.
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.
Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone CA,Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri MC, Mehta A, Kroemer G, Maiuri L, Raia V.
Cell Death Differ. 2016 Aug;23(8):1380-93. doi: 10.1038/cdd.2016.22. Epub 2016 Apr 1.
Abstract
We previously reported that the combination of two safe proteostasis regulators, cysteamine andepigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosistransmembrane conductance regulator (CFTR) in patients homozygous for the CFTR Phe508del mutation. Here we provide the proof-of-concept that this combination treatment restored CFTR function and reduced lung inflammation (P<0.001) in Phe508del/Phe508del or Phe508del/null-Cftr (but not in Cftr-null mice), provided that such mice were autophagy-competent. Primary nasal cells from patients bearing different class II CFTR mutations, either in homozygous or compound heterozygous form, responded to the treatment in vitro. We assessed individual responses to cysteamine plus EGCG in a single-centre, open-label phase-2 trial. The combination treatment decreased sweat chloride from baseline, increased both …
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE,Elborn JS. J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.
Abstract RATIONALE:
For patients with cystic fibrosis (CF), the use of inhaled antibiotics has become standard of care to suppress chronic Pseudomonas airways infection. There are limited antibiotic options formulated and approved for inhaled use and antibiotic efficacies attenuate over time, making additional inhaled antibiotic classes desirable. APT-1026 (levofloxacin inhalation solution, LIS) is a fluoroquinolone in development for management of chronic P. aeruginosa airways infection in patients with CF.
OBJECTIVES:
To compare the safety and efficacy of a 28-day course of treatment with LIS 240mg or placebo BID in persons ≥12years old with CF and chronic P. aeruginosa infection.
METHODS:
A multinational, randomized (2:1), double-blinded study of LIS and placebo over 28days in CF patients ≥12years with chronic P. aeruginosa infection. Time to exacerbation was the primary endpoint. FEV1 (% predicted) and patient-reported …
[Read the Article]
Since the legalization of marijuana in Colorado, there has been an increase in hospital visits and calls to regional poison centers due to unintentional marijuana exposure among young children. Researchers from the University of Colorado evaluated the number of children with exposures before and after recreational marijuana was legalized.
Between 2009 and 2015 they found a rise in the annual number of unintentional pediatric exposures. On average, these children were about two years old. Most children ingested the drug in edible forms such as candies and baked goods. Almost half of the patients seen in the children's hospital in the 2 years after legalization had exposures from recreational marijuana, suggesting that legalization did affect the incidence of exposures.
[Watch more videos of The JAMA Report]
[Read the Article]
Chronic use of prescription pain medications known as opioids is increasing in the United States. New research shows that a portion of patients undergoing several common surgical procedures may be at increased risk for chronic opioid use several months after surgery.
Researchers from Stanford University School of Medicine reviewed the records of more than 641,000 patients who underwent one of 11 common operations and were not taking opioid pain medication during the year prior to surgery.
They found that some patients were at an increased risk for chronic opioid use following surgery, with the risks ranging from about one and a half times more likely, to as high as five times more likely, depending on the procedure. Males and the elderly had a higher risk, as well as patients with a history of drug or alcohol abuse. The overall risk of chronic opioid use remained low at about 1 percent depending on the type of surgery.
[Watch more videos of The JAMA Report]
Host: Brian P. McDonough, MD, FAAFP
For most people, the home is a refuge and an oasis, a place to feel safe. But few ever wonder whether their homes and the everyday household items they use to clean and maintain them could be detrimental to their health.
Joining Dr. Brian McDonough to discuss the unsettling health risks behind common household items, and what consumers should keep an eye on, is Andre LaCroix, Vice President of Easy Breathe, Inc.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Joining Dr. Alan Brown to discuss the pharmacokinetic data behind drug interactions between treatments for complex lipid abnormalities is Dr. Barbara Wiggins, Pharm.D, clinical pharmacy specialist in cardiology at the Medical University of South Carolina and adjunct professor at the South Carolina School of Pharmacy. Dr. Wiggens has served as a member of the cardiovascular expert panel for the United States Pharmacopoeia.
Host: Michael Krychman, MD
There are many herbs and supplements that have gained popularity as natural sexual aphrodisiacs. While many are sold over the counter nationwide to enhance sexual function, a surprising number of supplements can cause ranges of serious side effects. Which aphrodisiacs have been proven effective, which are safe, and which are potentially deadly?
Host Dr. Michael Krychman joins Dr. Elizabeth West, a resident physician at the University of California-Irvine, to talk about the spectrum of natural herbs and supplements, from foods like honey and chocolate to herbs such as ginseng and macca, and their known sexual health benefits vs risks.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough speaks with Dr. Philip E. Empey, PharmD, PhD, Assistant Professor of Pharmacy and Therapeutics at the University of Pittsburg School of Pharmacy. Their discussion centers on advancements in genetic testing to detect variances in response to anticoagulation therapies for patients undergoing vascular procedures such as stent placements.
This week, hosts Mark Masselli and Margaret Flinter speak with Michael Botticelli, Director of the Office of National Drug Control Policy at the White House. The nation's "Drug Czar" talks about ONDCP's quest to battle the rising tide of opioid addiction and overdoses, now the leading cause of accidental death in America, by targeting resources towards more effective treatments and interventions.
This week, hosts Mark Masselli and Margaret Flinter speak with Dr. Marc Edwards, MacArthur Foundation Fellow and Virginia Tech-based Civil Engineer who uncovered the Flint water crisis, where residents were poisoned from high levels of lead and other contaminants through the municipal drinking water. Dr. Edwards discusses his efforts to uncover the crisis, and his team's efforts to mitigate the water contamination crisis and related health issues.
[Read the Article]
According to a new study, low dose aspirin taken regularly was associated with a reduced risk for cancer.
Researchers from Massachusetts General Hospital examined data from two large national studies that include about 136,000 men and women who have been providing detailed information about their overall health for decades.
Researchers identified 20,414 cancers among 88,084 women and 7,571 cancers among 47,881 men during a 32-year follow-up. Regular use of aspirin, two times or more per week, was associated with a 3 percent lower overall risk for cancer. This was mostly due to a 15 percent lower risk for gastrointestinal tract cancers and a 19 percent lower risk for cancers of the colon and rectum.
[Watch more videos of The JAMA Report]
Drug diversion is the illegal distribution or abuse of prescription drugs or their use for unintended purposes. The diversion of prescription drugs may occur at any point as prescription drugs are distributed from the manufacturer to wholesale distributors, to pharmacies, and ultimately to the patient. Though this problem is nearly universal among healthcare instititions, many don't have adequate processes in place to detect it. Moreover, concerns about civil and regulatory liability, as well as negative publicity, often impede healthcare organizations from reporting instances of drug diversion.
Dr. Howard Zucker, New York State Department of Health Commissioner, speaks with noted provider drug diversion expert Kimberly New, JD, BSN, RN about how prevalent the problem of drug diversion is, the signs of potential drug diversion activity, and how to set up a robust facility program to avert potential diversion events.
This program is provided on behalf of the New York One and Only Campaign, a public health effort led by the Centers for Disease Control and Prevention (CDC) and the Safe Injection Practices Coalition (SIPC) to raise awareness among patients and healthcare providers about safe injection practices.
Host: Jennifer Caudle, DO
States are cracking down on physicians and pharmacies in an attempt to curb a nationwide epidemic of opioid abuse. While some measures are improving the situation in hard-hit areas such as Florida, opponents say that the new laws are also keeping needed medications out of the hands of patients. How are states responding to this dual-issue, and do the ends of diminishing drug overdoses justify the means of restricting drug access to those who need them?
Host Jennifer Caudle, DO welcomes guests Nick Schilligo and Mark Bailey, DO, PhD to Everyday Family Medicine to discuss the pros and cons of updated opioid prescription regulations nationwide. Mr. Schilligo is Associate Vice President of State Government Affairs for the American Osteopathic Association, while Dr. Mark Bailey is Professor of Neurology and Pain Medicine specialist at the University of Alabama in Birmingham. This program was recorded on site at the American Osteopathic Association's annual medical education conference, OMED2015 in Orlando, FL,
[Read the Article]
Use of prescription drugs represents a major healthcare expense in the United States, and the number of adults taking prescription medications continues to increase. Researchers from the Harvard T.H. Chan School of Public Health examined trends in prescription drug use from 1999-2012 using data from nearly 40,000 adults, 20 years and older, who participated in the National Health and Nutrition Examination Survey. They found that the prevalence of prescription drug use increased from 51 percent in 1999-2000 to 59 percent in 2011-2012, while the use of five or more prescription drugs increased from 8 percent to 15 percent.
Eight of the 10 most commonly used drugs in 2011-2012 are used to treat components of the cardiometabolic syndrome, including high blood pressure, diabetes, and high cholesterol. Researchers note that the increase in use of several medications may reflect the growing need to treat obesity related complications. Use of antidepressants also increased from 7 percent in 1999-2000 to 13 percent in 2011-2012. The most commonly used individual drug was simvastatin, a medication used to treat high cholesterol. Simvastatin was used by 8 percent of the adult population in 2011-2012, up from 2.0 percent in 1999-2000.
Host: Matt Birnholz, MD
In today's clinical practice, there is no appropriate "one size fits all" treatment approach for COPD. But while this progressive trend toward personalized medicine standards helps optimize COPD care for each patient, the cost-to-benefit ratio for drug development changes as COPD evolves from one disease state into a larger disease spectrum. What is the current to future pipeline for drug R&D in the COPD arena, and is the horizon optimistic for delivering better treatment methods to patients? Joining Dr. Matt Birnholz to discuss the "Pulmonary Pipeline" is Dr. Nicholas Gross, pulmonologist and industry news reporter. Dr. Gross is emeritus professor of medicine and molecular biology at Loyola University in Chicago.
Host: John J. Russell, MD
Dr. John Russell welcomes author Deborah Blum to talk about her book, The Poisoner's Handbook.
In early twentieth-century New York, poisons offered an easy path to the perfect crime. Science had no place in the Tammany Hall-controlled coroner's office, and corruption ran rampant. However, with the appointment of chief medical examiner Charles Norris in 1918, the poison game changed forever. Together with toxicologist Alexander Gettler, the duo set the justice system on fire with their trailblazing scientific detective work, triumphing over seemingly unbeatable odds to become the pioneers of forensic chemistry and the gatekeepers of justice.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Joining host Dr. Alan Brown is Michael B. Bottorff, Pharm.D., Professor and Chair in the Department of Pharmacy Practice at South College School of Pharmacy in Knoxville, Tennessee. Dr. Bottorff will be reviewing generic medications, from manufacturing processes to approval measures.
Host: Linda Bernstein, Pharm.D.
In this edition of The Pharmacy Report®, host Dr. Linda Bernstein spotlights type 1 diabetes and the new paradigms of research in disease detection, prevention and treatment. In the Movers and Shakers segment, Dr. Stephen E. Gitelman, M.D., Professor of Clinical Pediatrics and Chair of Pediatric Diabetes and Clinical Research at the University of California, San Francisco shares his fascinating path of discovery and research into this complex disease and how someday it could revolutionize therapeutic approaches for not just the patient, but at-risk family members as well.
References mentioned in this segment:
- Diabetes Center, University of California, San Francisco
- Centers for Disease Control and Prevention's 2013 Tips From Former Smokers campaign, including 1-800-QUIT NOW, a number that links callers to their state quitlines. The website is www.cdc.gov/tips and features information on the campaign, as well as information on how to quit smoking from the National Cancer Institute's www.smokefree.gov
Host: Linda Bernstein, Pharm.D.
In this premiere edition of The Pharmacy Report®, host Dr. Linda Bernstein focuses on the growing threat of antimicrobial drug resistance. Top news stories include the CDC's "Threat Report 2013," and FDA drug and new indication approval updates. In this week's Movers and Shakers segment, Joseph Guglielmo, PharmD, Dean of the UCSF School of Pharmacy and a clinical pharmacist specialist in infectious disease will address antimicrobial stewardship and the role of the physician and pharmacist in these multidisciplinary programs.
References mentioned in this segment:
- Centers for Disease Control and Prevention:
Threat Report 2013 Antibioitic Resistance Threats in the United States, 2013 - Antimicrobial stewardship guidelines Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, and Hooton TM. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis. 2007 Jan 15;44(2):159-77
- IDSA REPORT: Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, …
Guest: Sean Yanchunas, Pharm.D, MBA
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough is joined by guest Sean Yanchunas, Clinical Content Manager and Workflow Subject Matter Expert at Catholic Health East Hospital Systems, to talk about the links between pharmacy and medical informatics.
Host: Brian P. McDonough, MD, FAAFP
Guest: Mark Moyad, MD, MPH
This discussion focuses on the current state of evidence behind vitamins, herbs, and supplements in popular demand. What does the latest research recommend for use, and what should we be avoiding? Featured is Dr. Mark Moyad, the Jenkins/Pokempner Director of Preventive & Complementary Medicine at the University of Michigan Medical Center. Dr, Brian McDonough hosts.
Host: Matt Birnholz, MD
Presenting this session of Grand Rounds is Dr. Leslie Boyer, founding director of the VIPER Institute in the College of Medicine at the University of Arizona.
This is Part 3 of a lecture in three parts.
Part 1 >>
Part 2 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Host: Matt Birnholz, MD
Presenting this session of Grand Rounds is Dr. Leslie Boyer, founding director of the VIPER Institute in the College of Medicine at the University of Arizona.
This is Part 2 of a lecture in three parts.
Part 1 >>
Part 3 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Host: Matt Birnholz, MD
Presenting this session of Grand Rounds is Dr. Leslie Boyer, founding director of the VIPER Institute in the College of Medicine at the University of Arizona.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Guest: Simon Jensen, MBChB, FACEM, BSc(Hons), MSc(Dist)
Host: Mary Leuchars, MD
How common are snake bites in various parts of the world, and how many of these are venomous? What are the symptoms of envenomation, and how widely does the venom vary among snake species? Dr. Simon Jensen, founding director of the Global Snake Bite Initiative and clinical research supervisor at the University of Papua New Guinea's snake bite research project, discusses methods and treatments for snake bites. Dr. Mary Leuchars hosts.
Host: Matt Birnholz, MD
The United States is in the grip of an epidemic of prescription drug overdoses. Over 27,000 people died from overdoses in 2007, a number that has risen five-fold since 1990 and has never been higher. Prescription drugs are now involved in more overdose deaths than heroin and cocaine combined.
For health professionals, policymakers and legislators, addressing this problem is complicated. While they push for education, prevention, and enforcement to reverse this epidemic, they must also ensure that patients with a legitimate need for these medications still have access to them. This important session of the CDC's Public Health Grand Rounds addressed these challenges and explored the innovative state and federal policies and interventions that are showing promise in reducing injury and death from this epidemic.
This is Part 3 of a 45-minute lecture in three parts.
Part 1 >>
Part 2 >>
To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/.
And for those interested in receiving continuing education credits for the live broadcasts of Public Health Grand Rounds, register at http://www2a.cdc.gov/TCEOnline.
CDC's participation in the activity is not meant to serve as …
Host: Matt Birnholz, MD
The United States is in the grip of an epidemic of prescription drug overdoses. Over 27,000 people died from overdoses in 2007, a number that has risen five-fold since 1990 and has never been higher. Prescription drugs are now involved in more overdose deaths than heroin and cocaine combined.
For health professionals, policymakers and legislators, addressing this problem is complicated. While they push for education, prevention, and enforcement to reverse this epidemic, they must also ensure that patients with a legitimate need for these medications still have access to them. This important session of the CDC's Public Health Grand Rounds addressed these challenges and explored the innovative state and federal policies and interventions that are showing promise in reducing injury and death from this epidemic.
This is Part 2 of a 45-minute lecture in three parts.
Part 1 >>
Part 3 >>
To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/
And for those interested in receiving continuing education credits for the live broadcasts of Public Health Grand Rounds, register at http://www2a.cdc.gov/TCEOnline.
CDC's participation in the activity is not meant to serve as an …
Host: Matt Birnholz, MD
The United States is in the grip of an epidemic of prescription drug overdoses. Over 27,000 people died from overdoses in 2007, a number that has risen five-fold since 1990 and has never been higher. Prescription drugs are now involved in more overdose deaths than heroin and cocaine combined.
For health professionals, policymakers and legislators, addressing this problem is complicated. While they push for education, prevention, and enforcement to reverse this epidemic, they must also ensure that patients with a legitimate need for these medications still have access to them. This important session of the CDC's Public Health Grand Rounds addressed these challenges and explored the innovative state and federal policies and interventions that are showing promise in reducing injury and death from this epidemic.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/
And for those interested in receiving continuing education credits for the live broadcasts of Public Health Grand Rounds, register at http://www2a.cdc.gov/TCEOnline.
CDC's participation in the activity is not meant to serve as an …
Guest: Tom Bartol
Host: Mimi Secor, DNP, FNP-BC, FAANP
As medicine takes an increasingly evidence-based approach to care, it's more important than ever for busy clinicians to be able to evaluate the benefits and risk-reduction associated with new treatments and medications. This week's guest, Tom Bartol, nurse practitioner at the Richmond Area Health Center in Richmond, Maine, discusses with host Mimi Secor how to wade through the research data and evaluate statistical significance versus clinical significance, and find the information you need in order to treat your patients more effectively.
Guest: Frances Toneguzzo, PhD
Host: Bruce Bloom, DDS, JD
Guest: David Borsook, MD, PhD
The discovery of a new use for a failed or existing drug has often been entirely serendipitous: a drug in development to treat angina failed, but became famous as Viagra when some of the test subjects reported interesting side effects. There are other notable examples, and now scientists are beginning to repurpose drugs in a more systematic way. How is drug repurposing research carried out, why is it important, and what are the hurdles to bringing these new uses to market? Hosted by Dr. Bruce Bloom.
Series Produced in Cooperation With
Guest: Arthur Holden, MBA
Host: Bruce Japsen
Two years after it was formed, the International Serious Adverse Event Consortium, working with the U.S. Food and Drug Administration, is making progress understanding why certain people are predisposed to dangerous drug interactions. Arthur Holdren, founder of the consortium, tells host Bruce Japsen about the discovery of a genetic link between liver injury and some people who received a popular antibiotic.
Guest: Robert Rapp, PharmD
Host: Charles Turck, PharmD, BCPS, BCCCP
The practice of pharmacy has certainly changed over the years, with pharmacy schools and pharmacists making an effort to become more patient-centered. Still, sometimes it takes a retrospective look through the eyes of a healthcare professional who experienced those changes as they happened, to truly appreciate just how far the practice of pharmacy has come, and just how far its place in healthcare has truly evolved over the past few decades. Dr. Robert Rapp, professor of pharmacy and professor of surgery at the University of Kentucky, chronicles pharmacy practice of decades past and previews how he believes the dynamic between pharmacists and other healthcare professionals will continue to progress in the years to come. Dr. Charles Turck hosts.
Guest: Gary Conkright
Host: Bruce Japsen
Reducing medication errors is a global challenge but the good news is that there are increasingly new and innovative ways companies are looking to find solutions to error reduction. Gary Conkright, chief executive officer of medication safety company InformMed tells host Bruce Japsen about a tool designed by nurses as the latest in the coming wave of potential products in the medication error solution space.
Guest: Mishka Terplan, MD
Host: Lisa Mazzullo, MD
Researchers have no way to determine how significant the problem of substance abuse and pregnancy really is. Very few women will be open and honest when it comes to answering questions about elicit drug use. So how do doctors get their patients the proper help? Dr. Mishka Terplan, an associate professor at the University of Chicago, looks at the issues of universal drug screening for all pregnant women, confidentiality, inpatient and outpatient drug rehabilitation programs and the stigma of being a substance abuser, with host Dr. Lisa Mazzullo.
Guest: Susan Foster, MSW
Host: Charles Turck, PharmD, BCPS, BCCCP
Up to 85 percent of all prescriptions purchased by patients on the Internet involve controlled substances, compared with just over 10 percent thru regular pharmacies. These figures, coming from independent, non-profit research, warn of serious problems of misuse by those who obtain drugs from the Web. What can be done-and what are we doing-to stop these sales? The National Center for Addiction and Substance Abuse (CASA) at Columbia University, has studied this issue extensively. Susan Foster, vice president and director of policy research and analysis at CASA, led the authoring of the Center's most recent report. She talks with host Dr. Charles Turck about what we can do to prevent unsupervised use of these medicines and better protect our patients from the associated dangers.
Guest: Susan Foster, MSW
Host: Charles Turck, PharmD, BCPS, BCCCP
We're learning more about the hundreds of Internet sites that advertise or sell controlled medications by mail. Yet a new set of answers brings a series of worrisome questions: How many of these websites actually require a prescription for controlled substances? Do many of those who buy prescription drugs online do so with nefarious intentions? Dr. Charles Turck probes problematic developments in online drug sales with Susan Foster, vice president and director of policy research and analysis at the National Center on Addiction and Substance Abuse at Columbia University. Ms. Foster directed the preparation of the Center's most recent You've Got Drugs report on spurious drug sales on the Internet.
Guest: Mark Willenbring, MD
Host: Larry Kaskel, MD
Given the pervasiveness of alcohol use disorders (AUDs) in the United States, Dr. Mark Willenbring says, “we need to be intervening at a much earlier stage and providing treatment to a much broader range of people then we currently do.” Dr. Willenbring, director of the National Institute on Alcohol Abuse and Alcoholism's Division of Treatment and Recovery Research, joins host Dr. Larry Kaskel to talk about new information from epidemiologic research on the prevalence and progression of heavy drinking and alcohol use disorders. In addition, Dr. Willenbring discusses the subtypes of alcohol dependence, and the nature of AUDs, in the context of DSM revisions.
Host: Larry Kaskel, MD
Guest: Gerald Dorn, MD
Should African American’s be treated with beta blockers to prevent heart failure? This has been a controversial question in the cardiovascular community. In this segment, Dr. Gerald Dorn of Washington University School of Medicine explains the biological mechanisms in which beta blockers offer protection from heart failure and what led him and his team to more closely examine the African American population who as a group does not seem to benefit as much from beta blockers. Learn in this segment about a gene variant identified by Dr. Dorn and his team carried by African American patients which provides protection from heart failure. Is this gene variant found in all African Americans? Are there other populations with this gene variant? Dr. Dorn talks about the implications of this study and where he hopes to go from here with his research.
Guest: Kathleen Jaeger, JD
Host: Bruce Japsen
Some physicians are still skittish about prescribing generic drugs, but the manufacturers of these less expensive medicines say they are increasingly important and there is less need to worry about their quality and safety than ever before. Kathleen Jaeger, president and CEO of the Generic Pharmaceutical Association, tells the Chicago Tribune's Bruce Japsen about the generic industry's assurances of quality, as well as regulations that have helped this cause.
Guest: Kathleen Jaeger, JD
Host: Bruce Japsen
Some of the most expensive drugs in the country are derived from biotechnology. But there is no law or regulatory pathway at the Food and Drug Administration to allow for cheaper biotech drugs such as those derived from chemicals like cholesterol pills or arthritis tablets with which doctors and their patients have become so familiar. Kathleen Jaeger, president and chief executive officer of the Generic Pharmaceutical Association tells the Chicago Tribune's Bruce Japsen about the state of the debate over a pathway for cheaper generic biotech drugs.
Guest: Jan Berger, MD
Host: Bruce Japsen
An unprecedented number of elderly leave their doctors' offices with prescriptions thanks to Medicare's drug benefits and the soaring number of aging baby boomers in need of medications. But did you know a large number of these patients don't get their prescriptions filled and don't adhere to what the doctor wrote for them? Dr. Jan Berger, Chief Clinical Officer for CVS/Caremark Corp. tells the Chicago Tribune's Bruce Japsen about the latest efforts of the pharmacy industry to get their patients to adhere to their medications.
Guest: David Bailey, PhD
Host: Larry Kaskel, MD
More than 40 drugs have been demonstrated to interact with grapefruit juice, primarily drugs that are first-pass metabolized. Join host Dr. Larry Kaskel and guest Dr. David Baily to discuss the serious nature of potential grapefruit juice/drug interactions and how best to communicate the required cautions to patients. Then learn of current research working to identify other natural foods that may modulate the absorbtion of drugs.
Guest: Jan Berger, MD
Host: Lauren Streicher, MD
An array of tools on the internet, coupled with direct-to-consumer marketing by pharmaceutical companies, have put us in a situation where patients obtain much of their medical knowledge from sources other than their personal physician. Dr. Jan Berger, senior vice president and chief clinical officer of CVS Caremark Corporation, outlines effective communication strategies that will help you ensure that your patients are receiving accurate medical information. Dr. Lauren Streicher hosts.
Guest: Jan Berger, MD
Host: Lauren Streicher, MD
Up to 50% of the prescriptions we write are never filled. Even when the patient does initiate recommended treatment, roughly half discontinue that treatment without informing or consulting their physicians. Medication management is one area that is showing increasing risk for medical liability as well as significant time and cost to the healthcare environment. Dr. Jan Berger discusses reducing liabilty.
Guest: Heather Hallen, PhD
Host: Paul Raeburn
The Death Cap mushroom. The Destroying Angel. Researchers are learning how these lethal mushrooms kill. Today we’re talking about some of the most dangerous and fiendishly clever organisms on earth: poisonous mushrooms. The names alone sound like something out of a B-movie: Deathcap and Destroying Angel. But how do these mushrooms kill? Researchers at Michigan State University who were studying the Death Cap mushroom thought they knew. They were looking for a big gene that produces a certain enzyme—the one that was supposed to do the damage. After years of trying and failing to sort out what was going on, they stumbled on something that was a complete surprise. Learn what they found--and get the latest advice on treating mushroom poisoning.
Guest: Marilyn Werber-Serafini
Host: Paul Raeburn
Biogenerics are generic versions of biotech drugs made from cells and other living organisms. They could save consumers and the health care system a lot of money. Here to tell us about them is a reporter who has been covering health care for National Journal for more than a decade. She written extensively about Medicare, the uninsured, and physicians.
Host: Todd Mahr, MD
Guest: Stephen Tilles, MD
Aspirin is something widely used in everyday practice, and generally well-tolerated. Yet, potentially serious adverse effects - sometimes leading to hospitalization - exist. Who's at risk? What are the symptoms, and can Aspirin desensitization work for all patients? Join Dr. Todd A. Mahr as he speaks with Dr. Stephen Tilles, clinical assistant professor at the University of Washington School of Medicine, in a discussion of aspirin intolerance.
Host: Todd Mahr, MD
Guest: Stephen Tilles, MD
How common is Aspirin Intolerance? When was it first discovered, and what are the clinical manifestations? Dr. Stephen Tilles, clinical assistant professor at the University of Washington School of Medicine, joins Dr. Todd A. Mahr to discuss aspirin intolerance, highlighting symptoms and provocative testing.
Guest: Nicholas Bergman, PhD
Host: Michael Benson, MD
In a scene from the recent Bruce Willis movie, Live Free or Die Hard, anthrax sensors were triggered, prompting evacuation of the FBI headquarters. Yet do such sensors really exist, or was this just another flight of Hollywood imagination? Our guest, Doctor Nicholas Bergman, reviews the nation's multi-faceted approach to defense against anthrax. Dr. Bergman received his PhD in biochemistry and molecular biology at the Massachusetts Institute of Technology. He is currently an Assistant Professor in the School of Biology at the Georgia Institute of Technology in Atlanta. He has published a paper examining some of the genomic properties of Anthrax in the Journal of Bacteriology.
Guest: Nicholas Bergman, PhD
Host: Michael Benson, MD
What do sheep, Islamic fascists and Vladimir Putin have in common? Anthrax. The "poor man’s" weapon of mass destruction, this disease has been recognized since Biblical times. Join our guest, Dr. Nicholas Bergman has his discusses the development of anthrax into a weapon of mass destruction. Dr. Bergman received his PhD in biochemistry and molecular biology at the Massachusetts Institute of Technology. He is currently an Assistant Professor in the School of Biology at the Georgia Institute of Technology in Atlanta. He has published a paper examining some of the genomic properties of Anthrax in the Journal of Bacteriology.
Guest: Nicholas Bergman, PhD
Host: Michael Benson, MD
Anthrax. Thought to be the sixth plague visited upon Pharoah in the Book of Exodus, the disease only causes episodic illness in humans. Yet it can cause a particularly gruesome death and can be easily treated if caught early. Our guest, Doctor Nicholas Bergman, explores the biology of naturally occurring anthrax infections in humans. Dr. Bergman received his PhD in biochemistry and molecular biology at the Massachusetts Institute of Technology. He is currently an Assistant Professor in the School of Biology at the Georgia Institute of Technology in Atlanta. He has published a novel paper examining some of the genomic properties of Anthrax in the Journal of Bacteriology.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.
Host: Paul Raeburn
Guest: Tod Cooperman, MD
Todd Cooperman, founder and president of Consumerlabs.com talks about some recent findings including traces of lead in multi-vitamins and a lack of regulatory control in in glucosamine-chondroitin compounds.